Somewhat Favorable News Coverage Somewhat Unlikely to Affect AtriCure (NASDAQ:ATRC) Stock Price

News stories about AtriCure (NASDAQ:ATRC) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AtriCure earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media headlines about the medical device company an impact score of 45.7784099724348 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment’s analysis:

AtriCure (NASDAQ:ATRC) opened at $17.69 on Friday. The company has a quick ratio of 1.65, a current ratio of 2.28 and a debt-to-equity ratio of 0.20. AtriCure has a 12 month low of $14.78 and a 12 month high of $25.18. The company has a market cap of $609.85, a P/E ratio of -17.34 and a beta of 0.66.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Wednesday, November 1st. The medical device company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.02. AtriCure had a negative net margin of 19.40% and a negative return on equity of 20.28%. The business had revenue of $42.20 million during the quarter, compared to analyst estimates of $43.44 million. During the same quarter last year, the firm posted ($0.21) earnings per share. The business’s revenue for the quarter was up 10.1% compared to the same quarter last year. sell-side analysts expect that AtriCure will post -0.96 EPS for the current year.

A number of analysts recently issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a $28.00 price target on shares of AtriCure in a report on Monday, October 9th. Piper Jaffray Companies reissued a “buy” rating and set a $24.00 price target on shares of AtriCure in a report on Sunday, December 10th. Needham & Company LLC decreased their price objective on shares of AtriCure from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, November 2nd. ValuEngine downgraded shares of AtriCure from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. Finally, TheStreet cut shares of AtriCure from a “c-” rating to a “d+” rating in a research report on Wednesday, November 29th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $24.67.

In related news, Director B Kristine Johnson acquired 1,500 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were bought at an average price of $18.36 per share, with a total value of $27,540.00. Following the completion of the acquisition, the director now owns 10,969 shares in the company, valued at $201,390.84. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO M. Andrew Wade sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $18.41, for a total transaction of $36,820.00. The disclosure for this sale can be found here. 11.90% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply